EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Reprint Email

Human Genome Sciences Inc (HGSI): Today's Featured Drugs Loser

By TheStreet Wire 05/24/12 - 05:01 PM EDT

Find out if (HGSI) is in Cramer's Portfolio.

Human Genome (HGSI) pushed the Drugs industry lower today making it today's featured Drugs loser. The industry as a whole closed the day up 1.6%. By the end of trading, Human Genome fell 26 cents (-1.9%) to $13.62 on average volume. Throughout the day, 6.7 million shares of Human Genome exchanged hands as compared to its average daily volume of eight million shares. The stock ranged in price between $13.41-$13.83 after having opened the day at $13.78 as compared to the previous trading day's close of $13.88. Other company's within the Drugs industry that declined today were: MediciNova (MNOV), down 42.9%, Catalyst Pharmaceutical Partners (CPRX), down 34.5%, Senesco Technologies (SNT), down 9.3%, and PROLOR Biotech (PBTH), down 5.9%.

Human Genome Sciences, Inc. operates as a biopharmaceutical company in the United States. Its principal products include BENLYSTA for systemic lupus erythematosus; and raxibacumab for inhalation anthrax. Human Genome has a market cap of $2.79 billion and is part of the health care sector. Shares are up 87.8% year to date as of the close of trading on Wednesday. Currently there are eight analysts that rate Human Genome a buy, no analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates Human Genome as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, generally disappointing historical performance in the stock itself and generally weak debt management.

You can view the full Human Genome Ratings Report.

On the positive front, Vermillion (VRML), up 47.9%, Rosetta Genomics (ROSG), up 44.9%, Telik (TELK), up 29.8%, and ARCA biopharma (ABIO), up 27%, were all gainers within the drugs industry with Merck (MRK) being today's featured drugs industry winner.

Use our drugs section to find industry-relevant news.
Or find some new ideas from our top rated stocks lists.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF (XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech (BIS).

Find other investment ideas from our top rated ETFs lists.

For more information on Human Genome Sciences Inc click any of the following:

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:

$2.5+ million portfolio
Large-cap and dividend focus
Intraday trade alerts from Cramer
Weekly roundups

TheStreet Quant Ratings

TRY IT FREE

New! $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:

Buy, hold, or sell recommendations for over 4,300 stocks
Unlimited research reports on your favorite stocks
A custom stock screener
Upgrade/downgrade alerts

Stocks Under $10

TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:

Model portfolio
Stocks trading below $10
Intraday trade alerts
Weekly roundups

Dividend Stock Advisor

TRY IT FREE

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:

Diversified model portfolio of dividend stocks
Alerts when market news affect the portfolio
Bi-weekly updates with exact steps to take - BUY, HOLD, SELL

Real Money Pro

TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:

Real Money + Doug Kass + 15 more Wall Street Pros
Intraday commentary & news
Ultra-actionable trading ideas

Options Profits

TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.